Compounds > imatinib mesylate
Page last updated: 2024-09-03

imatinib mesylate and Fibroma

imatinib mesylate has been researched along with Fibroma in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (50.00)29.6817
2010's3 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Blay, JY; Brain, EG; Bui, BN; Chabaud, S; Chevreau, C; Cupissol, D; Duffaud, F; Guillemet, C; Jimenez, M; Le Cesne, A; Mignot, L; Penel, N; Perol, D; Piperno-Neumann, S; Ray-Coquard, I1
Hartmann, JT; Horger, MS; Sauter, AW1
Bhutani, MS; Krishna, SG; Suzuki, R1
Baker, L; Hayes, C; Mace, J; McGinn, C; Sondak, V; Sybil Biermann, J; Thomas, D1
Bertucci, F; Delpero, JR; Di Stefano, D; Dubreuil, P; Gonçalves, A; Jacquemier, J; Monges, G; Noguchi, T; Palmerini, F; Sobol, H; Yang, Y1
Lagonigro, MS; Miselli, F; Negri, T; Pilotti, S; Pricl, S; Tamborini, E1

Trials

1 trial(s) available for imatinib mesylate and Fibroma

ArticleYear
Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2011, Volume: 22, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Disease Progression; Fibroma; Follow-Up Studies; Humans; Imatinib Mesylate; Middle Aged; Piperazines; Pyrimidines; Recurrence; Survival Analysis

2011

Other Studies

5 other study(ies) available for imatinib mesylate and Fibroma

ArticleYear
Monitoring response to imatinib using MRI signals in aggressive fibromatosis.
    European journal of nuclear medicine and molecular imaging, 2011, Volume: 38, Issue:2

    Topics: Benzamides; Female; Fibroma; Humans; Imatinib Mesylate; Magnetic Resonance Imaging; Piperazines; Pyrimidines; Treatment Outcome; Young Adult

2011
A first report of endoscopic ultrasound-guided biopsy in the diagnosis of desmoid-type fibromatosis.
    Endoscopy, 2011, Volume: 43 Suppl 2 UCTN

    Topics: Aged; Antineoplastic Agents; Benzamides; Biopsy, Fine-Needle; Endoscopy, Digestive System; Female; Fibroma; Humans; Imatinib Mesylate; Mesentery; Piperazines; Pyrimidines; Splenic Neoplasms; Tamoxifen; Ultrasonography, Interventional

2011
Response of extraabdominal desmoid tumors to therapy with imatinib mesylate.
    Cancer, 2002, Dec-01, Volume: 95, Issue:11

    Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Fibroma; Fibromatosis, Aggressive; Humans; Imatinib Mesylate; Male; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Salvage Therapy; Treatment Outcome

2002
Response of a KIT-positive extra-abdominal fibromatosis to imatinib mesylate and KIT genetic analysis.
    Journal of the National Cancer Institute, 2006, Apr-19, Volume: 98, Issue:8

    Topics: Adult; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Female; Fibroma; Germ-Line Mutation; Humans; Imatinib Mesylate; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha

2006
Re: Response of a KIT-positive extra-abdominal fibromatosis to imatinib mesylate and KIT genetic analysis.
    Journal of the National Cancer Institute, 2006, Nov-01, Volume: 98, Issue:21

    Topics: Alanine; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Cysteine; Fibroma; Humans; Imatinib Mesylate; Leucine; Methionine; Mutagenesis; Mutation; Piperazines; Polymorphism, Genetic; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Treatment Outcome

2006